Stay updated on DS8201a and Pembrolizumab in Advanced Cancer Clinical Trial
Sign up to get notified when there's something new on the DS8201a and Pembrolizumab in Advanced Cancer Clinical Trial page.

Latest updates to the DS8201a and Pembrolizumab in Advanced Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedNew Locations section added; state locations California, Connecticut, Florida, Maryland, Massachusetts, Missouri, Pennsylvania, and Texas are now listed, and the corresponding entries were removed. Revision updated to v3.3.3.SummaryDifference0.7%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedUpdates consist of release/version metadata (Revision: v3.3.2) and date stamps (e.g., 2025-11-18, 2027-03-31, 2025-11-17, 2025-11) that do not modify the core study content or its reported endpoints. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check50 days agoChange DetectedRemoved the administrative notice about funding lapse and government operating status. The study details and other page content remain unchanged.SummaryDifference0.3%

- Check71 days agoChange DetectedNo significant changes detected; the page content and structure are the same across screenshots.SummaryDifference0.3%

- Check93 days agoChange DetectedNew operating-status notice and version update to v3.2.0; previous v3.1.0 version tag removed.SummaryDifference2%

- Check100 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no other substantive content changes detected.SummaryDifference0.1%

Stay in the know with updates to DS8201a and Pembrolizumab in Advanced Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DS8201a and Pembrolizumab in Advanced Cancer Clinical Trial page.